Cutaneous vasculitis after COVID‐19 vaccination in a 41‐year‐old male. Issue 4 (22nd April 2023)

• Record Type: Journal Article
• Authors: Pournazari, Mehran; Assar, Shirin; Farsad, Faraneh; Mohamadzadeh, Dena
• Is Part Of: Clinical case reports. Volume 11:Issue 4(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2023-04-22
• Subjects: COVID‐19 infection -- cutaneous vasculitis -- leukocytoclastic vasculitis -- SARS‐CoV‐2 vaccine; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.7238
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Leukocytoclastic vasculitis could be a possible adverse event of different SARS‐CoV‐2 vaccines. Clinicians and manufacturers should be aware of this adverse event for appropriate diagnosis and treatment. Abstract : Cutaneous vasculitis has been associated with both Coronavirus disease‐2019 (COVID‐19) and SARS‐CoV‐2 vaccines. We reported a 41‐year‐old male who developed bullous lesions and erythematous plaques leading to atrophic patches 2 weeks after injection of the second dose of the COVID‐19 vaccine. The skin biopsy showed leukocytoclastic vasculitis. The disease was self‐limited and no recurrence of symptoms happened after 6 months of follow‐up.